http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 16:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++COMPUGEN+LTD+++++++++++++++++++++++++/26513596.html si-local-file:///var/storage/secattach/20260518/26513596.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++COMPUGEN+LTD+++++++++++++++++++++++++/26513596.html Mon, 18 May 2026 16:03:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++COMPUGEN+LTD+++++++++++++++++++++++++/26513596.html si-local-file:///var/storage/secattach/20260518/26513596.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++COMPUGEN+LTD+++++++++++++++++++++++++/26513596.html Mon, 18 May 2026 16:03:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++COMPUGEN+LTD+++++++++++++++++++++++++/26513596.html si-local-file:///var/storage/secattach/20260518/26513596.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++COMPUGEN+LTD+++++++++++++++++++++++++/26513596.html Mon, 18 May 2026 16:03:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/Earnings/Compugen+%28CGEN%29+Misses+Q1+EPS+by+1c/26510022.html <p>Compugen (NASDAQ: CGEN) reported Q1 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $1.63 million.</p><p>For earnings history and earnings-related data on Compugen (CGEN) <a href="http://www.streetinsider.com/ec_earnings.php?q=CGEN">click here</a>.</p> http://www.streetinsider.com/Earnings/Compugen+%28CGEN%29+Misses+Q1+EPS+by+1c/26510022.html Mon, 18 May 2026 07:02:37 -0400 CGEN http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/Press+Releases/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html <div class="xn-content"> <ul type="disc"><li>COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the <location value="LC/us" idsrc="xmltag.org" >U.S.</location>, <location value="LC/il" idsrc="xmltag.org" >Israel</location>, and <location value="LC/fr" idsrc="xmltag.org" >France</location>; interim analysis on track by Q1 2027</li><li>Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026</li><li>Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned</li><li>Solid financial position with cash runway expected to fund operations into 2029</li></ul><p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May http://www.streetinsider.com/PRNewswire/Compugen+Reports+First+Quarter+2026+Results/26509961.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN CW9 CW9 O.00653212 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+May+18/26509997.html si-local-file:///var/storage/secattach/20260518/26509997.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+May+18/26509997.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+May+18/26509997.html si-local-file:///var/storage/secattach/20260518/26509997.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+May+18/26509997.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+May+18/26509997.html si-local-file:///var/storage/secattach/20260518/26509997.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+May+18/26509997.html Mon, 18 May 2026 07:00:00 -0400 CGEN CGEN O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 <span>Stifel Virtual Targeted Oncology Forum</span>. The presentation will take place on <chron>Tuesday, May 19, 2026</chron>, at <chron>10:00-10:25 AM ET</chron>.</p> <p>A live webcast will be accessible on the Investor Relations section of the <span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen</span> website at <a target="_blank" href="https://www.cgen.com/overview/default.aspx" target="_blank" rel="nofollow">www.cgen.com</a>. A replay will also be available following the live http://www.streetinsider.com/PRNewswire/Compugen+to+Participate+in+2026+Stifel+Virtual+Targeted+Oncology+Forum/26472660.html Tue, 12 May 2026 07:00:00 -0400 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762